29°32’54″N
95°07’13″W
Back

Starlab Space and Frontier Space Technologies Announce Interest from Tier-1 Pharmaceutical Company in Future Research Aboard Starlab Commercial Space Station

HOUSTON—November 17, 2026—Starlab Space LLC and Frontier Space Technologies Ltd, a UK space biotechnology company developing in-orbit R&D and biomanufacturing platform technologies, today announced that a Tier-1 global pharmaceutical company has formally expressed interest in conducting research and development activities aboard the Starlab Space Station through payload capacity reserved by Frontier Space.

To enable this, Frontier Space has reserved four Middeck Locker Equivalent (MDLE) units of payload capacity during Starlab’s first year of operations. The Tier-1 pharmaceutical company has expressed interest in using a portion of this capacity for its research and development activities, leveraging Frontier Space’s biotechnology platforms developed for microgravity environments.

“Frontier Space’s reservation, and a Tier-1 pharmaceutical company’s interest in that capacity, is a clear signal of how quickly pharmaceutical demand for space-based R&D is growing,” said Marshall Smith, CEO of Starlab. “It gives companies like it a pathway to sustained access on Starlab, pairing their payload platforms with our research equipment, operational services and lab infrastructure so that work scales in orbit instead of running as a one-off experiment.”

“Frontier Space is building biotechnology platforms specifically designed to enable researchers to take advantage of the unique microgravity environment,” said Aqeel Shamsul, Ph.D., CEO of Frontier Space. “Our relationship with this leading pharmaceutical company demonstrates the potential for these platforms to become part of a sustained research program in space, ultimately enabled by the capabilities and recurring access provided by Starlab.”

The collaboration builds on Frontier Space’s reservation of Starlab capacity and establishes a pathway for long-term pharmaceutical R&D use of the commercial space station. Initial activities are expected to focus on developing scalable workflows and validating research approaches.

###

About Starlab 

Starlab Space is a U.S.-led, global joint venture among Voyager Technologies (NYSE: VOYG), Airbus, Mitsubishi Corporation, MDA Space, Palantir Technologies, and Space Applications Services, with strategic partners including Hilton, Journey, Northrop Grumman, and The Ohio State University. Starlab is developing a next-generation, AI-enabled commercial space station, aiming to ensure continued human presence in low-Earth orbit and a seamless transition of microgravity science and research alongside the retirement of the International Space Station. Starlab’s advanced, user-driven design and robust capabilities make it a premier platform for scientific discovery and technological advancement in space. For more information, visit starlab-space.com. 

About Frontier Space

Frontier Space is a UK space biotech company building platform technology to unlock the potential of pharmaceutical in-space biomanufacturing and research & development for the emerging commercial space industry. The company’s platform technologies, SpaceLab and XSB, aim to offer accessible, flexible, and scalable infrastructure for pharmaceutical R&D and biomanufacturing in orbit.

MEDIA CONTACT:  

Starlab Space 
Melissa Price, melissaprice@griffincg.com

Frontier Space

Anjali Sanjay, a.sanjay@frontier-space.co.uk 

29°32’54″N
95°07’13″W
Get
in Touch